Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 19/20 | 0.60 |
| ▸ | CDK12 | Q9NYV4 | 19/20 | 0.60 |
| ▸ | CDK7 | P50613 | 9/20 | 0.60 |
| ▸ | CCNH | P51946 | 9/20 | 0.60 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.55 |
| ▸ | CDK2 | P24941 | 12/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.52 |
| ▸ | CDK9 | P50750 | 10/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25595680 | 0.93 | CCNK (0.66) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL30204041 | 0.93 | CCNK (0.66) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL30260751 | 0.86 | CCNK (0.64) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL21178767 | 0.86 | CCNK (0.67) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL30439510 | 0.86 | CCNK (0.67) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL25595573 | 0.86 | CCNK (0.67) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL28817275 | 0.86 | CCNK (0.69) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL28817274 | 0.86 | CCNK (0.69) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL30204027 | 0.85 | CCNK (0.72) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL25595631 | 0.85 | CCNK (0.72) | CCNKCDK12CDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023040998-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-03-23 | — | — | WO | disclosed |